How to Apply the Canadian Obesity Clinical Practice Guidelines to People with Type 2 Diabetes
DOI:
https://doi.org/10.58931/cdet.2023.115Keywords:
obesity, type 2 diabetes, clinical practice guidelines, obesity managementAbstract
Approximately 90% of people with type 2 diabetes (T2D) have overweight or obesity. Thus, weight management is a highly relevant clinical issue in this patient population. However, studies of obesity treatment in people with T2D consistently show that people with T2D lose less weight than people who do not have diabetes. There are many reasons why weight loss can be more difficult to achieve for people with diabetes.
References
Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes: causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6):799-812. doi:10.1111/j.1463-1326.2006.00686.x DOI: https://doi.org/10.1111/j.1463-1326.2006.00686.x
Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38(6):1161-72. doi:10.2337/dc14-1630 DOI: https://doi.org/10.2337/dc14-1630
Pi-Sunyer FX. Weight loss in type 2 diabetic patients. Diabetes Care. 2005;28(6):1526-7. doi:10.2337/diacare.28.6.1526 DOI: https://doi.org/10.2337/diacare.28.6.1526
Krenke J, Tan T, Bloom S. Treating the obese diabetic. Expert Rev Clin Pharmacol. 2013;6(2):171-83. doi:10.1586/ecp.13.5 DOI: https://doi.org/10.1586/ecp.13.5
Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-86. doi:10.1016/S0140-6736(09)61457-4 DOI: https://doi.org/10.1016/S0140-6736(09)61457-4
Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-51. doi:10.1016/S0140-6736(17)33102-1 DOI: https://doi.org/10.1016/S0140-6736(17)33102-1
Lau DCW, Wharton S. Canadian adult obesity clinical practice guidelines: the science of obesity. Obesity Canada. 2020 Aug 4 [updated 2021 Mar 29; accessed 2022 Oct 30]. https://obesitycanada.ca/guidelines/science.
Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875-91. Appendix 2, 2020 clinical practice guidelines: 5As framework for obesity management in adults. doi:10.1503/cmaj.191707 DOI: https://doi.org/10.1503/cmaj.191707
Brown J, Clarke C, Johnson Stoklossa C, Sievenpiper J. Canadian adult obesity clinical practice guidelines: medical nutrition therapy in obesity management. Obesity Canada. 2022 Oct 21 [accessed 2022 Oct 30]. https://obesitycanada.ca/guidelines/nutrition.
Umpierre D, Ribeiro PAB, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305(17):1790-9. doi:10.1001/jama.2011.576 DOI: https://doi.org/10.1001/jama.2011.576
Boulé NG, Prud’homme D. Canadian adult obesity clinical practice guidelines: physical activity in obesity management. Obesity Canada. 2020 Aug 4 [updated 2021 Mar 29; accessed 2022 Oct 30]. https://obesitycanada.ca/guidelines/physicalactivity.
Pedersen SD, Manjoo P, Wharton S. Canadian adult obesity clinical practice guidelines: pharmacotherapy for obesity management. Obesity Canada. 2022 Oct 21 [accessed 2022 Oct 30]. https://obesitycanada.ca/guidelines/pharmacotherapy.
Kakotrichi P, Karagiannis T, Avgerinos I, Mantsiou C, Tousinas G, Manolopoulos A, et al. Comparative effects of medications for type 2 diabetes on body weight: a systematic review and network meta-analysis of 394 trials. Poster presented at: EASD 2020. 56th Annual Meeting of the European Association for the Study of Diabetes; 2020 Sept 21–25 [accessed 2022 Aug 28]. Abstract 535. https://www.easd.org/media-centre/#!resources/comparative-effects-of-medications-for-type-2-diabetes-on-body-weight-a-systematic-review-and-network-meta-analysis-of-394-trials-29a3e5d5-8a31-427b-b975-5a943b429159.
Berne C, et al. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabet Med. 2005;22(5):612-8. doi:10.1111/j.1464-5491.2004.01474.x DOI: https://doi.org/10.1111/j.1464-5491.2004.01474.x
Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022-9. doi:10.2337/dc13-0234 DOI: https://doi.org/10.2337/dc13-0234
Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085-93. doi:10.2337/dc19-1745 DOI: https://doi.org/10.2337/dc19-1745
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-84. doi:10.1016/S0140-6736(21)00213-0 DOI: https://doi.org/10.1016/S0140-6736(21)00213-0
Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11(4):361-71. doi:10.1111/j.1463-1326.2008.00970.x DOI: https://doi.org/10.1111/j.1463-1326.2008.00970.x
Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-88. doi:10.1172/JCI75276 DOI: https://doi.org/10.1172/JCI75276
Jelsing J, Vrang N, Hansen G, Raun K, Knudsen LB. Liraglutide: short-lived effect on gastric emptying—long lasting effects on body weight. Diabetes Obes Metab. 2012;14(6):531-8. doi:10.1111/j.1463-1326.2012.01557.x DOI: https://doi.org/10.1111/j.1463-1326.2012.01557.x
Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687-699. doi:10.1001/jama.2015.9676 DOI: https://doi.org/10.1001/jama.2015.9676
Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational Design of a Combination Medication for the Treatment of Obesity. Obes (Silver Spring). 2009;17(1):30-39. doi:10.1038/oby.2008.461 DOI: https://doi.org/10.1038/oby.2008.461
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-62. doi:10.1111/dom.14280 DOI: https://doi.org/10.1111/dom.14280
Biertho L, Hong D, Gagner M. Canadian adult obesity clinical practice guidelines: bariatric surgery: surgical options and outcomes. Obesity Canada. 2020 Aug 4 [updated 2021 Apr 14; accessed 2022 Aug 28]. https://obesitycanada.ca/guidelines/surgeryoptions.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes. N Engl J Med. 2017;376(7):641–651. doi:10.1056/NEJMoa1600869 DOI: https://doi.org/10.1056/NEJMoa1600869
Wharton S, Pedersen SD, Lau DCW, Sharma AM. Weight management in diabetes. Can J Diabetes. 2018;42 Suppl 1:S124-9. doi:10.1016/j.jcjd.2017.10.015 DOI: https://doi.org/10.1016/j.jcjd.2017.10.015
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-86. doi:10.2337/dci22-0034 DOI: https://doi.org/10.2337/dci22-0034
Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394-405. doi:10.1016/S0140-6736(21)01919-X DOI: https://doi.org/10.1016/S0140-6736(21)01919-X
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Canadian Diabetes & Endocrinology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
